Development and Validation of an Algorithm for Identifying Patients Undergoing Dialysis from Patients with Advanced Chronic Kidney Disease

Overview

Journal Clin Exp Nephrol

Publisher Springer

Specialty Nephrology

Date 2025 Jan 6

PMID 39762534

Authors

Takahiro Imaizumi

Takashi Yokota

Kouta Funakoshi

Kazushi Yasuda

Akiko Hattori

Akemi Morohashi

Tatsumi Kusakabe

Masumi Shojima

Sayoko Nagamine

Toshiaki Nakano

Yong Huang

Hiroshi Morinaga

Miki Ohta

Satomi Nagashima

Ryusuke Inoue

Naoki Nakamura

Hideki Ota

Tatsuya Maruyama

Hideo Gobara

Akira Endoh

Masahiko Ando

Yoshimune Shiratori

Shoichi Maruyama

Affiliations

Soon will be listed here.

Abstract

Background: Identifying patients on dialysis among those with an estimated glomerular filtration rate (eGFR) < 15 mL/min/1.73 m remains challenging. To facilitate clinical research in advanced chronic kidney disease (CKD) using electronic health records, we aimed to develop algorithms to identify dialysis patients using laboratory data obtained in routine practice.

Methods: We collected clinical data of patients with an eGFR < 15 mL/min/1.73 m from six clinical research core hospitals across Japan: four hospitals for the derivation cohort and two for the validation cohort. The candidate factors for the classification models were identified using logistic regression with stepwise backward selection. To ensure transplant patients were not included in the non-dialysis population, we excluded individuals with the disease code Z94.0.

Results: We collected data from 1142 patients, with 640 (56%) currently undergoing hemodialysis or peritoneal dialysis (PD), including 426 of 763 patients in the derivation cohort and 214 of 379 patients in the validation cohort. The prescription of PD solutions perfectly identified patients undergoing dialysis. After excluding patients prescribed PD solutions, seven laboratory parameters were included in the algorithm. The areas under the receiver operation characteristic curve were 0.95 and 0.98 and the positive and negative predictive values were 90.9% and 91.4% in the derivation cohort and 96.2% and 94.6% in the validation cohort, respectively. The calibrations were almost linear.

Conclusions: We identified patients on dialysis among those with an eGFR < 15 ml/min/1.73 m. This study paves the way for database research in nephrology, especially for patients with non-dialysis-dependent advanced CKD.

References

Levey A, Inker L, Matsushita K, Greene T, Willis K, Lewis E . GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis. 2014; 64(6):821-35. DOI: 10.1053/j.ajkd.2014.07.030. View

Inker L, Heerspink H, Tighiouart H, Levey A, Coresh J, Gansevoort R . GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials. J Am Soc Nephrol. 2019; 30(9):1735-1745. PMC: 6727261. DOI: 10.1681/ASN.2019010007. View

Yanagita M, Muto S, Nishiyama H, Ando Y, Hirata S, Doi K . Clinical questions and good practice statements of clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022. Clin Exp Nephrol. 2023; 28(2):85-122. PMC: 10808569. DOI: 10.1007/s10157-023-02415-0. View

Imaizumi T, Hamano T, Fujii N, Huang J, Xie D, Ricardo A . Cardiovascular disease history and β-blocker prescription patterns among Japanese and American patients with CKD: a cross-sectional study of the CRIC and CKD-JAC studies. Hypertens Res. 2021; 44(6):700-710. PMC: 8184630. DOI: 10.1038/s41440-020-00608-8. View

Imai E, Matsuo S, Makino H, Watanabe T, Akizawa T, Nitta K . Chronic Kidney Disease Japan Cohort (CKD-JAC) study: design and methods. Hypertens Res. 2008; 31(6):1101-7. DOI: 10.1291/hypres.31.1101. View

Imaizumi T, Fujii N, Hamano T, Yang W, Taguri M, Kansal M . Excess risk of cardiovascular events in patients in the United States vs. Japan with chronic kidney disease is mediated mainly by left ventricular structure and function. Kidney Int. 2023; 103(5):949-961. PMC: 10869952. DOI: 10.1016/j.kint.2023.01.008. View

Goto K, Imaizumi T, Hamada R, Ishikura K, Kosugi T, Narita I . Renal pathology in adult and paediatric population of Japan: review of the Japan renal biopsy registry database from 2007 to 2017. J Nephrol. 2023; 36(8):2257-2267. PMC: 10638177. DOI: 10.1007/s40620-023-01687-9. View

Urushihara M, Sato H, Shimizu A, Sugiyama H, Yokoyama H, Hataya H . Clinical and histological features in pediatric and adolescent/young adult patients with renal disease: a cross-sectional analysis of the Japan Renal Biopsy Registry (J-RBR). Clin Exp Nephrol. 2021; 25(9):1018-1026. DOI: 10.1007/s10157-021-02077-w. View

Berger M, Sox H, Willke R, Brixner D, Eichler H, Goettsch W . Good practices for real-world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making. Pharmacoepidemiol Drug Saf. 2017; 26(9):1033-1039. PMC: 5639372. DOI: 10.1002/pds.4297. View

10.

Zisis K, Pavi E, Geitona M, Athanasakis K . Real-world data: a comprehensive literature review on the barriers, challenges, and opportunities associated with their inclusion in the health technology assessment process. J Pharm Pharm Sci. 2024; 27:12302. PMC: 10932954. DOI: 10.3389/jpps.2024.12302. View

11.

Chen T, Knicely D, Grams M . Chronic Kidney Disease Diagnosis and Management: A Review. JAMA. 2019; 322(13):1294-1304. PMC: 7015670. DOI: 10.1001/jama.2019.14745. View

12.

Mol P, Thompson A, Heerspink H, Leufkens H . Precision medicine in diabetes and diabetic kidney disease: Regulatory considerations. Diabetes Obes Metab. 2018; 20 Suppl 3:19-23. PMC: 6220800. DOI: 10.1111/dom.13453. View

13.

Gregg E, Patorno E, Karter A, Mehta R, Huang E, White M . Use of Real-World Data in Population Science to Improve the Prevention and Care of Diabetes-Related Outcomes. Diabetes Care. 2023; 46(7):1316-1326. PMC: 10300521. DOI: 10.2337/dc22-1438. View

14.

Tonegawa-Kuji R, Kanaoka K, Iwanaga Y . Current status of real-world big data research in the cardiovascular field in Japan. J Cardiol. 2022; 81(3):307-315. DOI: 10.1016/j.jjcc.2022.09.006. View

15.

Yamaguchi M, Inomata S, Harada S, Matsuzaki Y, Kawaguchi M, Ujibe M . Establishment of the MID-NET medical information database network as a reliable and valuable database for drug safety assessments in Japan. Pharmacoepidemiol Drug Saf. 2019; 28(10):1395-1404. PMC: 6851601. DOI: 10.1002/pds.4879. View

16.

Sofue T, Nakagawa N, Kanda E, Nagasu H, Matsushita K, Nangaku M . Prevalence of anemia in patients with chronic kidney disease in Japan: A nationwide, cross-sectional cohort study using data from the Japan Chronic Kidney Disease Database (J-CKD-DB). PLoS One. 2020; 15(7):e0236132. PMC: 7371174. DOI: 10.1371/journal.pone.0236132. View

17.

Sofue T, Nakagawa N, Kanda E, Nagasu H, Matsushita K, Nangaku M . Prevalences of hyperuricemia and electrolyte abnormalities in patients with chronic kidney disease in Japan: A nationwide, cross-sectional cohort study using data from the Japan Chronic Kidney Disease Database (J-CKD-DB). PLoS One. 2020; 15(10):e0240402. PMC: 7561156. DOI: 10.1371/journal.pone.0240402. View

18.

Nakagawa N, Sofue T, Kanda E, Nagasu H, Matsushita K, Nangaku M . J-CKD-DB: a nationwide multicentre electronic health record-based chronic kidney disease database in Japan. Sci Rep. 2020; 10(1):7351. PMC: 7192920. DOI: 10.1038/s41598-020-64123-z. View

19.

Nagasu H, Yano Y, Kanegae H, Heerspink H, Nangaku M, Hirakawa Y . Kidney Outcomes Associated With SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs in Real-world Clinical Practice: The Japan Chronic Kidney Disease Database. Diabetes Care. 2021; 44(11):2542-2551. PMC: 8546274. DOI: 10.2337/dc21-1081. View

20.

Agarwal R, Sinha A, Cramer A, Balmes-Fenwick M, Dickinson J, Ouyang F . Chlorthalidone for Hypertension in Advanced Chronic Kidney Disease. N Engl J Med. 2021; 385(27):2507-2519. PMC: 9119310. DOI: 10.1056/NEJMoa2110730. View